Patent US5344822A successfully refreshed from Google Patents.
US5344822A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods useful in endotoxin prophylaxis and therapy
Assignee: Rogosin Institute Inc
•
Filing: 1992-08-12
•
Granted: 1994-09-06
•
Expires: 2012-08-12
Abstract
Abstract Treatment and prophylaxis of endotoxin caused toxicity is disclosed. This is accomplished by administering a lipid into which the endotoxin of concern is associated, preferably together with a peptide which is not an apolipoprotein. Preferably, the two components are administered in the form of a reconstituted particle, although this is by no means required.
Inventors
- 👤 Daniel M. Levine
- 👤 Thomas S. Parker
- 👤 Albert L. Rubin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 17:21
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61K31/683; A61K31/685; A61K9/00; A61K9/10; A61K9/127; A61K9/1275; A61P; A61P3/00; A61P3/06; A61P39/00; A61P39/02; C; C07; C07K; C07K14/00; C07K14/435; C07K14/775; A61K38/00; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
67 words
Method for alleviating endotoxin caused toxicity in a subject comprising administering to a subject in need thereof an amount of (i) a peptide consisting of the amino acid sequence set forth in SEQ ID NO; 1 and (ii) a phosphatidylcholine, wherein (i) and (ii) are present in the form of an HDL like particle with which said endotoxin associates, in an amount sufficient to alleviate said toxicity.
Claim 2
Dependent Claim
67 words
Method for alleviating endotoxin caused toxicity in a subject comprising administering to a subject in need thereof an amount of (i) a peptide consisting of the amino acid sequence set forth in SEQ ID NO; 1 and (ii) a phosphatidylcholine, wherein (i) and (ii) are present in the form of an HDL like particle with which said endotoxin associates, in an amount sufficient to alleviate said toxicity.
Claim 3
Dependent Claim
12 words
Method of claim 1, wherein said endotoxin is an E. coli endotoxin.
Claim 4
Dependent Claim
12 words
Method of claim 1, wherein said endotoxin is an S. tymphimurium endotoxin.
Claim 5
Dependent Claim
61 words
Method for alleviating endotoxin caused toxicity in a subject comprising administering to a subject in need thereof, separate and consecutive administrations of (i) a peptide consisting of the amino acid sequence f SEQ ID NO: 1 and (ii) a phosphatidylcholine with which said endotoxin associates, wherein (i) and (ii) are administered in an amount of each sufficient to alleviate said toxicity.
Claim 6
Dependent Claim
61 words
Method for alleviating endotoxin caused toxicity in a subject comprising administering to a subject in need thereof, separate and consecutive administrations of (i) a peptide consisting of the amino acid sequence f SEQ ID NO: 1 and (ii) a phosphatidylcholine with which said endotoxin associates, wherein (i) and (ii) are administered in an amount of each sufficient to alleviate said toxicity.
Claim 7
Dependent Claim
12 words
Method of claim 4, wherein said endotoxin is an E. coli endotoxin.
Claim 8
Dependent Claim
12 words
Method of claim 4, wherein said endotoxin is an S. typhimurium endotoxin.
Claim 9
Dependent Claim
79 words
Method for reducing risk of endotoxin caused toxicity in a subject comprising administering to a subject who is to be subjected to exposure to an endotoxin an amount of (i) a peptide consisting of the amino acid sequence set forth in SEQ ID NO 1 and (ii) a phosphatidylcholine with which said endotoxin associates, wherein (i) and (ii) are present in the form of an HDL like particle, in an amount sufficient to reduce risk of endotoxin caused toxicity.
Claim 10
Dependent Claim
79 words
Method for reducing risk of endotoxin caused toxicity in a subject comprising administering to a subject who is to be subjected to exposure to an endotoxin an amount of (i) a peptide consisting of the amino acid sequence set forth in SEQ ID NO 1 and (ii) a phosphatidylcholine with which said endotoxin associates, wherein (i) and (ii) are present in the form of an HDL like particle, in an amount sufficient to reduce risk of endotoxin caused toxicity.
References Cited (Backward Citations)
US5128318A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-09-05 | 1998-03-07 | 1998-09-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-09-05 | 2002-03-07 | 2002-09-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-09-05 | 2006-03-07 | 2006-09-06 | $7700.00 | Window Closed / Lapsed |